We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protein Hydrolyzation and Glycemic Control

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01034618
First Posted: December 17, 2009
Last Update Posted: December 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Maastricht University Medical Center
December 16, 2009
December 17, 2009
December 17, 2009
December 2007
October 2008   (Final data collection date for primary outcome measure)
Glucose and insulin homeostasis.
Same as current
No Changes Posted
Plasma amino acid profiles
Same as current
Not Provided
Not Provided
 
Protein Hydrolyzation and Glycemic Control
The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes
The insulinotropic effects of protein hydrolysate/amino acid ingestion have been shown to regulate blood glucose homeostasis in both type 2 diabetes patients and normoglycemic controls. The objective of the study is to investigate the optimal dose of such an insulinotropic mixture.
Not Provided
Interventional
Not Provided
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Diabetes
Dietary Supplement: Protein hydrolyzation
  • Placebo Comparator: Placebo
    Intervention: Dietary Supplement: Protein hydrolyzation
  • Experimental: Intact protein
    Intervention: Dietary Supplement: Protein hydrolyzation
  • Experimental: Protein hydrolysate
    Intervention: Dietary Supplement: Protein hydrolyzation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2009
October 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male
  • Age between 40 and 70 years
  • Oral blood glucose lowering medication
  • BMI < 35 kg/m2

Exclusion Criteria:

  • Exogenous insulin use
  • Cardiac disease (any cardiac event in the last 5 years)
  • Diabetic complications (microvascular complications, microalbuminuria: albumin:creatinine ratio >2,5)
Sexes Eligible for Study: Male
40 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
 
NCT01034618
06-3-081
No
Not Provided
Not Provided
Ralph J.F. Manders, PhD, Maastricht University Medical Center
Maastricht University Medical Center
Not Provided
Not Provided
Maastricht University Medical Center
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP